Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer

Featuring Jeanne Tie, MBChB, MD


Professor Jeanne Tie, MBChB, FRACP, MD, Peter MacCallum Cancer Centre, Victoria, Australia, discusses results from the AGITG DYNAMIC-Rectal study, which explored a circulating tumor DNA (ctDNA)-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.

The study showed that a ctDNA-guided approach was associated with a reduced rate of adjuvant chemotherapy administration, though the small sample size in the trial does not allow any conclusions to be drawn about the non-inferiority of a ctDNA-guided approach in comparison to standard management.

The data confirms a lower risk of recurrence for patients with undetectable post-operative ctDNA.


Source:

Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: The randomized AGITG DYNAMIC-Rectal study. Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract 12

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Advertisement

Advertisement

Advertisement

Advertisement